UroGen Pharma Ltd.
For the period ended Dec 31, 2025. Filed Mar 2, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 2, 2026
URGN$25.32-3.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Revenue | $109,788 | $90,398 |
| Cost of revenue | 12,447 | 8,881 |
| Gross profit | 97,341 | 81,517 |
| Operating expenses: | ||
| Research and development expenses | 67,107 | 57,145 |
| Selling, general and administrative expenses | 155,097 | 121,154 |
| Operating loss | (124,863) | (96,782) |
| Financing on prepaid forward obligation | (18,503) | (23,411) |
| Interest expense on long-term debt | (15,345) | (12,521) |
| Interest and other income, net | 5,295 | 8,672 |
| Loss before income taxes | (153,416) | (124,042) |
| Income tax expense | (78) | (2,832) |
| Net Loss | $(153,494) | $(126,874) |
| Statements of Comprehensive Loss | ||
| Net loss | $(153,494) | $(126,874) |
| Other comprehensive loss | ||
| Unrealized income (loss) on investments | (37) | 44 |
| Comprehensive Loss | $(153,531) | $(126,830) |
| Net loss per ordinary share - basic and diluted | $(3.19) | $(2.96) |
| Weighted average number of shares outstanding used in computation of basic and diluted loss per ordinary share | 48,116,098 | 42,876,737 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.